P/B
15,5
AtaiBeckley
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
$2.7B
Market Cap • 9/10/2026
2020
(6 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,5
EPS
—
Market Cap
Market Cap
2,7B
EV
2,5B
EV/Revenue
0
EV/EBITDA
0
EV/EBIT
0
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-1,4B
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
1,4%
% Goodwill
0,1%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-100%
CAGR Op. Income 5Y
-100%
CAGR Net Income 5Y
-42,3%
CAGR OCF 5Y
-100%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
8,6
Quick Ratio
7,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!